We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Find out how you could do the SFI actions for integrated pest management.
This review comments on some improvements in influenza management and promising vaccine development platforms
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Data on the real-world efficacy of the COVID-19 vaccines.
Background information and advice on coronavirus (COVID-19) for health and care professionals.
Information and resources on the UK’s plans to see antimicrobial resistance contained and controlled by 2040.
Clinical advice on West Nile virus including symptoms, diagnosis and epidemiology.
Projects granted during 2014 that have a primary purpose of basic research into the immune system.
How investigators and sponsors should manage clinical trials during COVID-19
Find out about the SFI actions for integrated pest management, what land is eligible for each action, and what you need to do to get paid.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine rozanolixizumab (Rystiggo) to treat adults with generalised myasthenia gravis, an autoimmune disease that causes muscle weakness, which can affect multiple muscle groups throughout the...
The Vaccine Development Evaluation Centre (VDEC) at Porton Down in Wiltshire facilitates the development and evaluation of new vaccines and therapeutics.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.